AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28368672 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive arm (idarubicin 9 mg/m2 daily for 3 days)
Number of subjects: 293
Study 28368672 — intervention group
Group type: COMPARATOR
Intervention: Standard arm (idarubicin 9 mg/m2 daily for 2 days)
Number of subjects: 293
Study 28368672 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive arm
Number of subjects: 293
Study 28368672 — intervention group
Group type: COMPARATOR
Intervention: Standard arm
Number of subjects: 293
Study 25381472 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided corticosteroid injection (40 mg/1 ml methylprednisolone acetate)
Number of subjects: 74
Study 25381472 — intervention group
Group type: COMPARATOR
Intervention: Blinded corticosteroid injection (40 mg/1 ml methylprednisolone acetate)
Number of subjects: 74
Study 25381472 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (USG and BIG)
Number of subjects: 74
Study 23991656 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual thrombus aspiration followed by PCI
Number of subjects: 7244
Study 23991656 — intervention group
Group type: COMPARATOR
Intervention: PCI only
Number of subjects: 7244
Study 22080022 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad libitum feeding regimen
Number of subjects: 6
Study 22080022 — intervention group
Group type: COMPARATOR
Intervention: Restrict feeding regimen
Number of subjects: 6
Study 22080022 — intervention group
Group type: EXPERIMENTAL
Intervention: Different turkey genotypes
Number of subjects: 6
Study 22080022 — intervention group
Group type: EXPERIMENTAL
Intervention: Different feeding regimens
Number of subjects: 6
Study 22080022 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA methodology
Number of subjects: 6
Study 18815153 — intervention group
Group type: EXPERIMENTAL
Intervention: Modular behavioural education programme
Number of subjects: 218
Study 18815153 — intervention group
Group type: COMPARATOR
Intervention: Standard information-focused education programme
Number of subjects: 218
Study 17062303 — intervention group
Group type: EXPERIMENTAL
Intervention: IV pantoprazole 160 mg/d for 3 days
Number of subjects: 40
Study 17062303 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 160 mg/d for 3 days
Number of subjects: 40
Study 14597860 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 360 mg/day plus hypocaloric diet
Number of subjects: 204
Study 14597860 — intervention group
Group type: COMPARATOR
Intervention: Calorie‐restricted diet alone
Number of subjects: 204
Study 10954007 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (50 mg losartan daily and 10 mg enalapril daily)
Number of subjects: 177
Study 10954007 — intervention group
Group type: COMPARATOR
Intervention: Losartan (50 mg daily)
Number of subjects: 177
Study 10954007 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (10 mg daily)
Number of subjects: 177
Study 8598621 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg of zileuton four times daily
Number of subjects: 401
Study 8598621 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 401
Study 8598621 — intervention group
Group type: COMPARATOR
Intervention: 600 mg of zileuton, 400 mg of zileuton, or placebo
Number of subjects: 401
Study 1421877 — intervention group
Group type: EXPERIMENTAL
Intervention: iv dexamethasone (n = 12)
Number of subjects: 25
Study 1421877 — intervention group
Group type: COMPARATOR
Intervention: sham injections (n = 13)
Number of subjects: 25
Study 6092309 — intervention group
Group type: EXPERIMENTAL
Intervention: COF (Cytoxan, Vincristin, and 5‐fluorouracil)
Number of subjects: 43
Study 6092309 — intervention group
Group type: EXPERIMENTAL
Intervention: COFP (Cytoxan, Vincristin, 5‐Fu and Procabazine)
Number of subjects: 43
Study 6092309 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage II
Number of subjects: 43
Study 6092309 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage III
Number of subjects: 43
Study 6092309 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients alive without evidence of disease
Number of subjects: 43
Study 30107967 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care (POC) test
Number of subjects: 197
Study 30107967 — intervention group
Group type: COMPARATOR
Intervention: Core laboratory (lab) test
Number of subjects: 197
Study 27893064 — intervention group
Group type: COMPARATOR
Intervention: Lower-protein group (1 g of bovine protein/100 mL of breast milk)
Number of subjects: 60
Study 27893064 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-protein group (1.8 g of bovine protein/100 mL of breast milk or individualized high-protein supplementation)
Number of subjects: 60
Study 27893064 — intervention group
Group type: COMPARATOR
Intervention: Lower-protein group
Number of subjects: 60
Study 27893064 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-protein group
Number of subjects: 60
Study 26304778 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage of Change (SOC) tailored intervention
Number of subjects: 242
Study 26304778 — intervention group
Group type: COMPARATOR
Intervention: Standard ergonomics advice
Number of subjects: 242
Study 24330475 — intervention group
Group type: EXPERIMENTAL
Intervention: LVD-ADV combination therapy
Number of subjects: 72
Study 24330475 — intervention group
Group type: COMPARATOR
Intervention: ADV monotherapy
Number of subjects: 72
Study 21977923 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of 300,000 IU of vitamin D3
Number of subjects: 45
Study 21977923 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vitamin D injection)
Number of subjects: 45
Study 21126639 — intervention group
Group type: EXPERIMENTAL
Intervention: Coapsys ventricular reshaping
Number of subjects: 165
Study 21126639 — intervention group
Group type: COMPARATOR
Intervention: Control (indicated surgery: either coronary artery bypass graft alone or coronary artery bypass graft with mitral valve repair)
Number of subjects: 165
Study 17878495 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined thyroxine and triiodothyronine treatment
Number of subjects: 9
Study 17878495 — intervention group
Group type: COMPARATOR
Intervention: Thyroxine alone
Number of subjects: 9
Study 15809670 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent androgen deprivation therapy
Number of subjects: 76
Study 11992421 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking for 30 years or more
Number of subjects: 89835
Study 11992421 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 89835
Study 10221694 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlangen metal catheter
Number of subjects: 320
Study 10221694 — intervention group
Group type: COMPARATOR
Intervention: Wallace catheter
Number of subjects: 320
Study 10221694 — intervention group
Group type: EXPERIMENTAL
Intervention: Both catheters
Number of subjects: 320
Study 10221694 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal-transmyometrial transfer
Number of subjects: 320
Study 7880949 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure measurement by a doctor
Number of subjects: 0
Study 7880949 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure measurement by a nurse
Number of subjects: 0
Study 7880949 — intervention group
Group type: COMPARATOR
Intervention: Comparison of nurse and doctor measurements
Number of subjects: 0
Study 2204739 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (325 mg every other day)
Number of subjects: 22071
Study 2204739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22071
Study 386675 — intervention group
Group type: EXPERIMENTAL
Intervention: Enterobiotic (oxytetracycline + neomycin)
Number of subjects: 75
Study 386675 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 75
Study 30940426 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluidotherapy (40 °C, 20 minutes in continuous mode, 5 sessions/week)
Number of subjects: 30
Study 30940426 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation program (5 days/week, 2‐4 hours/day)
Number of subjects: 30
Study 28409530 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital cervical stretching
Number of subjects: 0
Study 28409530 — intervention group
Group type: COMPARATOR
Intervention: Control (no digital cervical stretching)
Number of subjects: 0
Study 25443867 — intervention group
Group type: EXPERIMENTAL
Intervention: Staying Healthy‐Asthma Responsible & Prepared program
Number of subjects: 205
Study 25443867 — intervention group
Group type: COMPARATOR
Intervention: All students (including control)
Number of subjects: 205
Study 23712975 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance exercise training (CET) program
Number of subjects: 27
Study 23712975 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study 21856879 — intervention group
Group type: EXPERIMENTAL
Intervention: iScreen® photorefractive device
Number of subjects: 169
Study 21856879 — intervention group
Group type: EXPERIMENTAL
Intervention: iScreen® photorefractive device in developmentally-at-risk children
Number of subjects: 169
Study 21856879 — intervention group
Group type: COMPARATOR
Intervention: iScreen® photorefractive device in children without developmentally-at-risk factors
Number of subjects: 169
Study 19884558 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral therapy (BT) sleep intervention (Individualized Sleep Promotion Plan [ISPP])
Number of subjects: 219
Study 19884558 — intervention group
Group type: COMPARATOR
Intervention: Healthy eating control (HEC)
Number of subjects: 219
Study 19884558 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral therapy (BT)
Number of subjects: 219
Study 17438255 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (900 to 3600 mg/d for 8 weeks)
Number of subjects: 135
Study 17438255 — intervention group
Group type: COMPARATOR
Intervention: Lactose placebo
Number of subjects: 135
Study 16294457 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg 17beta‐estradiol/0.125 mg trimegestone
Number of subjects: 13
Study 16294457 — intervention group
Group type: COMPARATOR
Intervention: 2 mg 17beta‐estradiol/1 mg norethisterone acetate
Number of subjects: 13
Study 16294457 — intervention group
Group type: COMPARATOR
Intervention: 1 mg 17beta‐estradiol/0.5 mg norethisterone acetate
Number of subjects: 13
Study 12040347 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin phase A (1.0 mg/kg bolus, infusion of 2.5 mg/kg/h for 4 hours) plus abciximab
Number of subjects: 268
Study 12040347 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin phase B (0.5 mg/kg bolus, infusion of 1.75 mg/kg/h for the procedure duration) plus provisional abciximab
Number of subjects: 268
Study 12040347 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin phase C (0.75 mg/kg bolus, infusion of 1.75 mg/kg/h for the procedure duration) plus provisional abciximab
Number of subjects: 268
Study 12040347 — intervention group
Group type: COMPARATOR
Intervention: Heparin plus planned abciximab
Number of subjects: 268
Study 9883403 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracervical anesthesia (10 ml of 1.5 mepivacaine)
Number of subjects: 72
Study 9883403 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 72
Study 8584295 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg four times a day for 4 weeks
Number of subjects: 21
Study 8584295 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 8584295 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 21
Study 2122724 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorbitol (70%, 0 to 60 mL daily for 4 weeks)
Number of subjects: 30
Study 2122724 — intervention group
Group type: COMPARATOR
Intervention: Lactulose (for 4 weeks)
Number of subjects: 30
Study 2122724 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorbitol
Number of subjects: 30
Study 2122724 — intervention group
Group type: COMPARATOR
Intervention: Lactulose
Number of subjects: 30
Study 392079 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (300 mg)
Number of subjects: 1705
Study 31563483 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered local anaesthetic (10:1 dilution of 8.4% sodium bicarbonate with 2% lignocaine hydrochloride with adrenaline 1:80,000)
Number of subjects: 60
Study 31563483 — intervention group
Group type: COMPARATOR
Intervention: Control group (2% lignocaine hydrochloride with adrenaline 1:80,000 without bicarbonate)
Number of subjects: 60
Study 27808556 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-Focused Therapy (PFT)
Number of subjects: 199
Study 27808556 — intervention group
Group type: EXPERIMENTAL
Intervention: Child Life and Attention Skills Program (CLAS)
Number of subjects: 199
Study 27808556 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual
Number of subjects: 199
Study 28011807 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-minute brief intervention delivered by school learning mentors and a leaflet on alcohol.
Number of subjects: 470
Study 28011807 — intervention group
Group type: COMPARATOR
Intervention: Usual school-based practice and a leaflet on a healthy lifestyle (excluding alcohol).
Number of subjects: 470
Study 25243536 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 304
Study 25243536 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 304
Study 25243536 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training
Number of subjects: 304
Study 25243536 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 304
Study 22510550 — intervention group
Group type: EXPERIMENTAL
Intervention: Short stretch support bandage, immobilized for four days
Number of subjects: 38
Study 22510550 — intervention group
Group type: COMPARATOR
Intervention: Two-layer compression bandage (Pro-Guide), mobilized one day after operation
Number of subjects: 38
Study 20581801 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain-computer interface-based games (20 sessions over 10 weeks)
Number of subjects: 10
Study 20581801 — intervention group
Group type: COMPARATOR
Intervention: Age- and gender-matched controls
Number of subjects: 10
Study 17485423 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CYC)
Number of subjects: 158
Study 17485423 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study 15727575 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisone for 2 weeks and intranasal budesonide for 12 months
Number of subjects: 109
Study 15727575 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery and intranasal budesonide for 12 months
Number of subjects: 109
Study 15727575 — intervention group
Group type: COMPARATOR
Intervention: Spanish general population
Number of subjects: 109
Study 12095905 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms of depression
Number of subjects: 2657
Study 12095905 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-rated health
Number of subjects: 2657
Study 12095905 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms of anxiety
Number of subjects: 2657
Study 12095905 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of hospitalization
Number of subjects: 2657
Study 12095905 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-rated health (measured closest to time of death)
Number of subjects: 2657
Study 10631762 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 micrograms CCK‐4
Number of subjects: 27
Study 10631762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 7595708 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine (NVB) 30 mg/m2 weekly
Number of subjects: 183
Study 7595708 — intervention group
Group type: COMPARATOR
Intervention: Melphalan (ALK) 25 mg/m2 every 4 weeks
Number of subjects: 183
Study 2245951 — intervention group
Group type: EXPERIMENTAL
Intervention: morphine‐scopolamine
Number of subjects: 101
Study 2245951 — intervention group
Group type: EXPERIMENTAL
Intervention: pethidine
Number of subjects: 101
Study 2245951 — intervention group
Group type: EXPERIMENTAL
Intervention: midazolam
Number of subjects: 101
Study 382821 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol
Number of subjects: 15
Study 382821 — intervention group
Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 15
Study 30571659 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal brachytherapy
Number of subjects: 0
Study 30571659 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study 30571659 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiation
Number of subjects: 0
Study 30571659 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiotherapy
Number of subjects: 0
Study 28857719 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate 10 mg
Number of subjects: 0
Study 28857719 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate 30 mg
Number of subjects: 0
Study 28857719 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate 50 mg
Number of subjects: 0
Study 28857719 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate 70 mg
Number of subjects: 0
Study 28857719 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28857719 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (all doses combined)
Number of subjects: 0
Study 25425024 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity stimulation programme during the child's first year
Number of subjects: 143
Study 25425024 — intervention group
Group type: COMPARATOR
Intervention: Control group (no activity stimulation programme)
Number of subjects: 143
Study 23610455 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy treatment with radiotherapy
Number of subjects: 0
Study 23610455 — intervention group
Group type: COMPARATOR
Intervention: Standard method (censored at time of death)
Number of subjects: 0
Study 21305536 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose omeprazole (80-mg bolus followed by 8-mg/h infusion for 72 hours)
Number of subjects: 122
Study 21305536 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose omeprazole (40-mg intravenous infusion once daily for 3 days)
Number of subjects: 122
Study 21305536 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose omeprazole
Number of subjects: 122
Study 21305536 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose omeprazole
Number of subjects: 122
Study 19344191 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim XM02 (5 microg/kg)
Number of subjects: 36
Study 19344191 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim XM02 (10 microg/kg)
Number of subjects: 36
Study 19344191 — intervention group
Group type: COMPARATOR
Intervention: Neupogen (5 microg/kg)
Number of subjects: 36
Study 19344191 — intervention group
Group type: COMPARATOR
Intervention: Neupogen (10 microg/kg)
Number of subjects: 36
Study 19344191 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim XM02 and Neupogen
Number of subjects: 36
Study 17213880 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular prenatal exercise
Number of subjects: 0
Study 17213880 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss programs incorporating diet and exercise
Number of subjects: 0
Study 17213880 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular exercise following conception
Number of subjects: 0
Study 15253847 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercessory prayer for 1 month directed toward a life concern or problem disclosed by the participant at baseline.
Number of subjects: 86
Study 15253847 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intercessory prayer).
Number of subjects: 86
Study 11793037 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 receptor antagonists (basiliximab and daclizumab)
Number of subjects: 35
Study 11793037 — intervention group
Group type: COMPARATOR
Intervention: No induction
Number of subjects: 35
Study 9408981 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1: single daily dose of netilmicin based upon weight, age and renal function (mean dose 298 +/- 29 mg, median 300 mg, range 250-350 mg)
Number of subjects: 80
Study 9408981 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2: 150% of standard dose (mean 418 +/- 45 mg, median 400 mg, range 350-500 mg)
Number of subjects: 80
Study 9408981 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3: 200% of standard dose (mean 525 +/- 41 mg, median 500 mg, range 400-550 mg)
Number of subjects: 80
Study 9408981 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 4: 250% of standard dose (mean 710 +/- 39 mg, median 650 mg, range 600-750 mg)
Number of subjects: 80
Study 8254242 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy added to best medical care including aspirin and control of manageable risk factors
Number of subjects: 0
Study 8254242 — intervention group
Group type: COMPARATOR
Intervention: Best medical care including aspirin and control of manageable risk factors
Number of subjects: 0
Study 3545965 — intervention group
Group type: EXPERIMENTAL
Intervention: arbaprostil (10 micrograms q.i.d. for 4 wk)
Number of subjects: 82
Study 3545965 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 82
Study 31866488 — intervention group
Group type: EXPERIMENTAL
Intervention: Video decision support aid
Number of subjects: 250
Study 31866488 — intervention group
Group type: COMPARATOR
Intervention: Attention-control arm (booklet about advance directives)
Number of subjects: 250
Study 30893320 — intervention group
Group type: EXPERIMENTAL
Intervention: Dedicated hematology units
Number of subjects: 2330
Study 30893320 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission through hematology services
Number of subjects: 2330
Study 30893320 — intervention group
Group type: COMPARATOR
Intervention: Dedicated emergency facilities
Number of subjects: 2330
Study 30893320 — intervention group
Group type: COMPARATOR
Intervention: Observation facilities
Number of subjects: 2330
Study 29354950 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with medication (once a day, five times per week, for 6 weeks, total 30 times)
Number of subjects: 64
Study 29354950 — intervention group
Group type: COMPARATOR
Intervention: Control group (maintained original treatment with antihypertensive medication)
Number of subjects: 64
Study 29354950 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with medication
Number of subjects: 64